Efficacy and Safety of Anlotinib, Irinotecan and Temozolomide in the Treatment of Refractory or Recurrent Neuroblastoma in Children: an Open, Single Arm, Single Center, Phase II Clinical Study
Clinical trial NCT04842526 · UNKNOWN
Trial details
- NCT number
- NCT04842526
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-12
- Primary completion
- 2023-12-31
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.